US00843l163B2
`
`
`
`
`
`
`
`(12) United States Patent
`Baldassarre et al.
`
`
`
`
`
`
`(10) Patent N0.:
`
`
`(45) Date of Patent:
`
`
`
`
`US 8,431,163 B2
`
`
`
`*Apr. 30, 2013
`
`
`
`
`
`
`
`
`
`
`EP
`
`WO
`
`WO
`
`WO
`
`
`
`
`FOREIGN PATENT DOCUMENTS
`
`
`1682672
`7/2006
`
`
`W02005004884
`1/2005
`
`
`W02006127907
`11/2006
`
`
`2/2010
`W02010019540
`
`
`OTHER PUBLICATIONS
`
`
`Kieler-Jensen et al., “Inhaled nitric oxide in the evaluation of heart
`
`
`
`
`
`
`
`
`transplant candidates with elevated pulmonary vascular resistance”,
`
`
`
`
`
`
`
`J. Heart Lung Transplant, vol. 13, pp. 366-375 (1994).
`
`
`
`
`
`
`
`
`
`Kinsella et al., “Inhaled nitric oxide in premature neonates with
`
`
`
`
`
`
`
`
`severe hypoxaemic respiratory faliure: a randomised controlled
`
`
`
`
`
`
`trial,” The Lancet, vol. 354, pp. 1061-1065 (1999).
`
`
`
`
`
`
`
`
`Konduri et al., “A Randomized Trial ofEarlyVersus Standard Inhaled
`
`
`
`
`
`
`
`Nitric Oxide Therapy in Term and Near-Term Newborn Infants with
`
`
`
`
`
`
`
`
`
`Hypoxic Respiratory Failure,” Pediatrics, vol. 113 No. 3, pp. 559-564
`
`
`
`
`
`
`
`
`
`(2004).
`
`Krasuski et al., “Inhaled Nitric Oxide Selectively Dilates Pulmonary
`
`
`
`
`
`
`
`Vasculature in Adult Patients With Pulmonary Hypertension, Irre-
`
`
`
`
`
`
`
`spective of Etiology,” Journal ofthe American College of Cardiology
`
`
`
`
`
`(JACC), vol. 36, No. 7, pp. 2204-2211 (2000).
`
`
`
`
`
`
`
`Krohn, “Effect of inhaled nitric oxide on left ventricular and pulmo-
`
`
`
`
`
`
`
`
`
`nary vascular function,” The Journal of Thoracic and Cardiovascular
`
`
`
`
`
`
`
`
`Surgery, vol. 117(1), pp. 195-196 (1999).
`
`
`
`
`
`
`Kulik, “Inhaled nitric oxide in the management of congenital heart
`
`
`
`
`
`
`
`
`disease,” Current Opinion in Cardiology, vol. 11, pp. 75-80 (1996).
`
`
`
`
`
`
`
`
`
`Lavigne et al., “Cardiovascular Outcomes of Pediatric Seroreverters
`
`
`
`
`
`
`Perinatally Exposed to HAART,” Cardiovascular Toxicology, vol. 4,
`
`
`
`
`
`
`pp. 187-197 (2004).
`
`
`
`Letter ofAcceptance for AU 2010202422, dated Oct. 7, 2010.
`
`
`
`
`
`
`
`Letter of acceptance of AU application 2009202685, dated Aug. 10,
`
`
`
`
`
`
`2010, 3 pages.
`
`
`Lipschultz, “The effect of dexrazoxane on myocardial injury in
`
`
`
`
`
`
`
`
`doxorubicin-treated children with acute lymphoblastic leukemia,”
`
`
`
`
`
`New England Journal of Medicine, vol. 351, pp. 145-153 (2004).
`
`
`
`
`
`
`
`
`
`Lipschultz, “The incidence of pediatric cardiomyopathy in two
`
`
`
`
`
`
`
`regions ofthe United States,” New England Journal ofMedicine, Apr.
`
`
`
`
`
`
`
`
`2003.
`<<http://www.nejm.org/doi/full/10.1056/
`24,
`
`
`
`NEJMoa021715>>.
`
`Lipshultz, “Ventricular dysfunction clinical research in infants, chil-
`
`
`
`
`
`
`
`dren and adolescents,” Progress in Pediatric Cardiology, vol. 12, pp.
`
`
`
`
`
`
`
`
`
`1-28 (2000).
`
`
`Lipshultz, “Chronic Progressive Cardiac Dysfunction Years After
`
`
`
`
`
`
`
`Doxorubicin Therapy for Childhood Acute Lymphoblastic Leuke-
`
`
`
`
`
`
`
`mia,” Journal of Clinical Oncology, vol. 23, No. 12, 8 pages (2005).
`
`
`
`
`
`
`
`
`
`
`Lipshultz, “Clinical research directions in pediatric cardiology,” Cur-
`
`
`
`
`
`
`
`rent Opinion in Pediatrics, vol. 21, pp. 585-593 (2009).
`
`
`
`
`
`
`
`
`Lipshultz, “Establishing norms for echocardiographic measurement
`
`
`
`
`
`of cardiovascular structures and function in children,” J. Appl.
`
`
`
`
`
`
`
`
`Physiol., vol. 99, pp. 386-388 (2005).
`
`
`
`
`
`
`Lipshultz et al., “Cardiovascular status of infants and children of
`
`
`
`
`
`
`
`
`
`women infected with HIV-1 (P2C2 HIV): a cohort study,” The Lan-
`
`
`
`
`
`
`
`
`
`
`cet, vol. 360, pp. 368-373 (2002).
`
`
`
`
`
`
`Lipshultz et al., “Cardiovascular Trials in Long-Term Survivors of
`
`
`
`
`
`
`
`Childhood Cancer,” Journal ofClinical Oncology, vol. 22, No. 5, pp.
`
`
`
`
`
`
`
`
`
`769-773 (2004).
`
`
`Lipshultz et al., “Long-Term Enalapril Therapy for Left Ventricular
`
`
`
`
`
`
`
`Dysfunction in Doxorubicin-Treated Survivors of Childhood Can-
`
`
`
`
`
`cer,” Journal of Clinical Oncology, vol. 20, No. 23, pp. 4517-4522
`
`
`
`
`
`
`
`
`
`
`(2002).
`
`Lipshultz, “Frequency of clinically unsuspected myocardial injury at
`
`
`
`
`
`
`a children’s hospital,” American Heart Journal, vol. 151, No. 4, pp.
`
`
`
`
`
`
`
`
`
`
`916-922 (2006).
`
`
`
`(54) METHODS OF REDUCING THE RISK OF
`
`
`
`
`
`OCCURRENCE OF PULMONARY EDEMA
`
`
`
`ASSOCIATED WITH INHALATION OF
`
`
`
`NITRIC OXIDE GAS
`
`
`
`
`(71) Applicant: INO Therapeutics LLC, Hampton, NJ
`
`
`
`
`
`
`(US)
`
`
`(72)
`
`
`Inventors: James S. Baldassarre, Doylestown, PA
`
`
`
`
`(US); Ralf Rosskamp, Chester, NJ (US)
`
`
`
`
`
`
`(73) Assignee:
`
`
`
`INO Therapeutics LLC, Hampton, NJ
`
`
`
`
`(US)
`
`
`( * ) Notice:
`
`
`
`
`Subject to any disclaimer, the term of this
`
`
`
`
`
`
`patent is extended or adjusted under 35
`
`
`
`
`U.S.C. 154(b) by 0 days.
`
`
`
`This patent is subject to a terminal dis-
`
`
`
`
`
`claimer.
`
`
`
`
`
`(21) Appl.No.: 13/651,660
`
`(22)
`
`
`
`Filed:
`
`
`Oct. 15, 2012
`
`
`
`
`(65)
`
`
`
`Prior Publication Data
`
`
`
`US 2013/0040000 A1
`Feb. 14,2013
`
`
`
`
`
`
`Related U.S. Application Data
`
`
`
`
`(63) Continuation of application No. 12/821,041, filed on
`
`
`
`
`
`
`
`Jun. 22, 2010, now Pat. No. 8,293,284, which is a
`
`
`
`
`
`
`
`
`continuation of application No. 12/494,598, filed on
`
`
`
`
`
`Jun. 30, 2009, now abandoned.
`
`
`
`
`
`
`(51)
`
`
`(2006.01)
`
`(2006.01)
`
`(2006.01)
`
`(2006.01)
`
`
`Int. Cl.
`
`
`A01N 59/00
`
`
`A61K 33/00
`
`
`C01B 21/24
`
`
`A6]M 16/00
`
`
`(52) U.S. Cl.
`
`
`USPC ..................... .. 424/718; 128/200.24; 423/405
`
`
`
`
`
`(58) Field of Classification Search ...................... .. None
`
`
`
`
`
`See application file for complete search history.
`
`
`
`
`
`
`
`
`
`
`(56)
`
`
`
`
`References Cited
`
`
`U.S. PATENT DOCUMENTS
`
`
`
`9/1996 Bathe etal.
`
`
`
`7/1997 Briendetal.
`
`
`2/1999 Zapolet al.
`
`
`
`5/2000 Zapolet al.
`
`
`
`11/2000 Headet al.
`
`
`
`8/2003 Bloch et al.
`
`
`
`7/2009 Rothbard et al.
`
`
`
`12/2002 Krebs
`
`
`
`7/2003 Stenzler
`
`
`
`6/2004 Whitehurst et al.
`
`
`
`
`1/2009 Oppenheimer et al.
`
`
`
`
`1/2009 Elliott
`
`
`
`6/2009 Starket al.
`
`
`
`
`7/2009 Blackburn et al.
`
`
`
`
`
`5,558,083 A
`
`5,651,358 A
`
`5,873,359 A
`
`6,063,407 A
`
`6,142,147 A
`
`6,601,580 B1
`
`
`7,557,087 B2
`
`
`2002/0185126 A1
`
`
`2003/0131848 A1
`
`
`2004/0106954 A1
`
`
`2009/0018136 A1
`
`
`2009/0029371 A1
`
`
`2009/0149541 A1
`
`
`2009/0176772 A1
`
`
`
`(Continued)
`
`
`Primary Examiner — Ernst Arnold
`
`
`
`(74) Attorney, Agent, or Firm — Fish & Richardson P.C.
`
`
`
`
`
`(57)
`ABSTRACT
`
`
`Disclosed are methods of reducing the risk of occurrence of
`
`
`
`
`
`
`
`pulmonary edema associated with a medical treatment com-
`
`
`
`
`
`
`
`prising inhalation of nitric oxide gas.
`
`
`
`
`
`25 Claims, No Drawings
`
`
`
`
`
`
`
`001
`
`PRAXAIR ET AL. 1001
`
`001
`
`

`
`
`
`US 8,431,163 B2
`Page 2
`
`
`
`
`OTHER PUBLICATIONS
`
`
`Loh et al ., “Cardiovascular Effects ofInhaled Nitric Oxide in Patients
`
`
`
`
`
`
`
`with Left Ventricular Dsyfunction,” Circulation, vol. 90, pp. 2780-
`
`
`
`
`
`
`
`
`
`2785 (1994).
`
`
`Macrae et al., “Inhaled nitric oxide therapy in neonates and children:
`
`
`
`
`
`
`
`
`
`reaching a European consensus,” Intensive Care Med., vol. 30, pp.
`
`
`
`
`
`
`
`
`
`372-380 (2004).
`
`
`Madriago et al., “Heart Failure in Infants and Children,” Pediatrics in
`
`
`
`
`
`
`
`
`Review, vol. 31, pp. 4-12 (2010).
`
`
`
`
`
`
`Magee et al., “Comparison of Supplemental Oxygen and Nitric
`
`
`
`
`
`
`
`Oxide for Inhalation plus oxygen in the evaluation ofthe reactivity of
`
`
`
`
`
`
`
`the pulmonary vasculature during Acute PulmonaryVasodilator Test-
`
`
`
`
`
`
`
`ing,” Oct. 1, 2004-Oct. 31, 2006, Research project description,
`1
`
`
`
`
`
`
`
`
`page, http://Www.rbht.nhs.uldresearch.
`
`
`Vlalloy, “Nitric Oxide Weaning, RT: for Decision Makers in Respi-
`
`
`
`
`
`
`
`
`
`ratory Care,” http://rtmagazine.com/issues/articles/2000-12_05.
`
`
`
`asp, 3 pages, Dec. 2000.
`
`
`
`
`Vlartinez et al., “Dermatological Cryosurgery in Primary Care with
`
`
`
`
`
`
`
`Dimethyl Ether Propane Spray in Comparison with Liquid Nitro-
`
`
`
`
`
`
`
`
`gen,” Atnecion Primaria, vol. 18, No. 5, pp. 211 and 216 (1996).
`
`
`
`
`
`
`
`
`
`
`
`Vlatsumoto et al., “Effect of Inhaled Nitric Oxide on Gas Exchange in
`
`
`
`
`
`
`
`
`Patients with Congestive Heart Failure,” Annals ofInternal Medicine,
`
`
`
`
`
`
`
`
`vol. 130, No. 1, pp. 40-44 (1999).
`
`
`
`
`
`
`Vleyler’s Side Effects of Drugs: The International Encyclopedia of
`
`
`
`
`
`
`
`Adverse Drug Reactions and Interactions, Nitric Oxide, Fifteenth
`
`
`
`
`
`
`
`
`Edition, Elsevier B.V (2006).
`
`
`
`
`Vlichelakis et al., “Oral Sildenafil Is an Effective and Specific Pul-
`
`
`
`
`
`
`
`
`
`monary Vasodilator in Patients with Pulmonary Arterial Hyperten-
`
`
`
`
`
`
`
`sion: Comparison with Inhaled Nitric Oxide,” Circulation vol. 105,
`
`
`
`
`
`
`
`
`
`pp. 2398-2403 (2002).
`
`
`
`Vliller et al., “Nutrition in Pediatric Cardiomyopathy,” Prog. Pediatr.
`
`
`
`
`
`
`
`Cardiol. vol. 24(1), pp. 59-71 (2007).
`
`
`
`
`
`
`\/lone, “Effects of Environmental Exposures on the Cardiovascular
`
`
`
`
`
`
`System: Prenatal Period Through Adolescence,” Pediatrics. vol. 1 13,
`
`
`
`
`
`
`
`
`\Io. 4, pp. 1058-1069 (2004).
`
`
`
`
`Vlorales-Blanhir et al., “Clinical value of vasodilator test with
`
`
`
`
`
`
`
`
`inhaled nitric oxide for predicting long-term response to oral
`
`
`
`
`
`
`
`
`
`vasodilators in pulmonary hypertension,” Respiratory Medicine, vol.
`
`
`
`
`
`
`98, pp. 225-234 (2004).
`
`
`
`
`Vloss et al., “Moss and Adams’ Heart Disease in Infants, Children,
`
`
`
`
`
`
`
`
`
`and Adolescents,” Coarctation of the Aorta, vol. 1, p. 991 in part
`
`
`
`
`
`
`
`
`
`
`(2007).
`
`Vlurray, “Angiotensin Converting Enzyme Inhibitory Peptides
`
`
`
`
`
`
`Derived from Food Proteins: Biochemistry, Bioactivity and Produc-
`
`
`
`
`
`
`
`
`tion,” Current Pharmaceutical Design, pp. 773-791 (2007).
`
`
`
`
`
`
`
`Vlurray et al., “Nitric Oxide and Septic Vascular Dysfunction,”
`
`
`
`
`
`
`
`
`Anesth. Analg. vol. 90, pp. 89-101 (2000).
`
`
`
`
`
`
`
`\Tatori et al., “Inhaled Nitric Oxide Modifies Left Ventricular Dias-
`
`
`
`
`
`
`
`
`
`tolic Stress in the Presence of Vasoactive Agents in Heart Failure,”
`
`
`
`
`
`
`
`
`Am. J. Respir Crit. Care Med, vol. 167, pp. 895-901 (2003).
`
`
`
`
`
`
`
`
`
`
`\TIH CC: Critical Care Services, http://www.cc.nih.gov/ccmd/clini-
`
`
`
`
`
`
`cal_services.html; retrieved Mar. 10, 2011, 3 pages.
`
`
`
`
`
`
`“NIH Clinical Center 2 Critical Care Medicine Department Sample
`
`
`
`
`
`
`
`
`Rotations, Updated Jan. 2007 <<http://www.cc.nih.gov/ccmd/prof_
`
`
`
`
`
`opps/rotation.html>>”.
`
`NIH Clinical Center Services, retrieved at <http://www.cc.nih.gov/
`
`
`
`
`
`ccmd/clinical_services.html>> on Aug. 18, 2010.
`
`
`
`
`NIH Clinical Center, Department Policy and Procedure Manual for
`
`
`
`
`
`
`
`
`the Critical Care Therapy and Respiratory Care Section; Nitric Oxide
`
`
`
`
`
`
`
`
`
`
`Therapy, sections 3.1-3.1.2 & 5.2.3 (2000).
`
`
`
`
`
`NIH Clinical Center 2 Critical Care Medicine Department Sample
`
`
`
`
`
`
`
`
`Rotations, Updated Jan. 2007.
`
`
`
`
`Notification of Reason for Rejection, mailed Jul. 30, 2010, from
`
`
`
`
`
`
`
`
`
`Japanese Patent Application No. 2009-157623.
`
`
`
`
`
`Office Action for AU 2010202422 dated Jul. 9, 2010, 3 pages.
`
`
`
`
`
`
`
`
`Office Action from AU 2009202685 dated Mar. 15, 2010.
`
`
`
`
`
`
`
`
`Office Action from AU 2010206032 dated Aug. 16, 2010 (3 pages).
`
`
`
`
`
`
`
`
`
`Office Action Response for AU 2009202685 to Mar. 15, 2010 OA,
`
`
`
`
`
`
`
`
`
`filed Jun. 8, 2010 (16 pages).
`
`
`
`
`
`Office Action Response for JP2007157623 filed on Nov. 12, 2009 (no
`
`
`
`
`
`
`
`
`English translation).
`
`
`Office Action Response to AU 2010202422 OA dated Jul. 9, 2010,
`
`
`
`
`
`
`
`response filed Sep. 1, 2010.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`002
`
`wwW.fda.gov/doWnloads/Drugs/
`
`GuidanceComplianceRegulatorylnformation/Guidance/
`ucm073087.pdf, Mar. 1995.
`
`
`
`Office Action in U.S. Appl. No. 12/494,598, mailed Aug. 13, 2010
`
`
`
`
`
`
`
`
`
`(26 pages).
`
`
`Notice ofAbandonment in U.S. Appl. No. 12/494,598, mailed Sep.
`
`
`
`
`
`
`
`10, 2010 (2 pages).
`
`
`
`Office Action in U.S. Appl. No. 12/820,866, mailed Sep. 23, 2010 (26
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Lee & Hayes, Reply Amendment (Accelerated Exam-Transmittal
`
`
`
`
`
`Amendment/Reply) in U.S. Appl. No. 12/820,866 mailed Sep. 23,
`
`
`
`
`
`
`
`2010, filed Oct. 1, 2010 (22 pages).
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/820,866, mailed Nov. 2, 2010 (25
`
`
`
`
`
`
`
`
`
`pages).
`
`Lee & Hayes, Reply Amendment (Accelerated Exam-Transmittal
`
`
`
`
`
`
`Amendment/Reply) in U.S. Appl. No. 12/820,866 mailed Nov. 2,
`
`
`
`
`
`
`
`2010, filed Jan. 14, 2011 (12 pages).
`
`
`
`
`
`
`
`Advisory Action in U.S. Appl. No. 12/820,866, mailed Feb. 23, 2011
`
`
`
`
`
`
`
`
`
`(2 pages).
`
`
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`
`
`
`
`
`
`Amendment/Reply) in U.S. Appl. No. 12/820,866 mailed Sep. 23,
`
`
`
`
`
`
`
`2010, filed Mar. 1, 2011 (9 pages).
`
`
`
`
`
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`
`
`
`
`
`
`AmendmentJReply) in U.S. Appl. No. 12/820,866 mailed Sep. 23,
`
`
`
`
`
`
`
`2010, filed Mar. 1, 2011 (5 pages).
`
`
`
`
`
`Advisory Action in U.S. Appl. No. 12/820,866, mailed Mar. 25, 2011
`
`
`
`
`
`
`
`
`
`(3 pages).
`
`
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`
`
`
`
`
`
`
`AmendmentJReply) in U.S. Appl. No. 12/820,866 mailed Nov. 2,
`
`
`
`
`
`
`
`2010, filed May 2, 2011 (9 pages).
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/820,866, mailed Jun. 8, 2011 (32
`
`
`
`
`
`
`
`
`
`pages).
`
`Office Action in U.S. Appl. No. 12/820,866, Aug. 24, 2011 (23
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., Reply Brief in U.S. Appl. No. 12/820,866,
`
`
`
`
`
`
`
`
`filed Dec. 16,2011 (21 pages).
`
`
`
`
`
`Fish & Richardson, P.C., Supplement to Reply Brief in U.S. Appl.
`
`
`
`
`
`
`
`No. 12/820,866, filed Jan. 3, 2012 (3 pages).
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/820,980, mailed Aug. 17, 2010
`
`
`
`
`
`
`
`
`
`(33 pages).
`
`
`Lee & Hayes, Reply Amendment in U.S. Appl. No. 12/820,980,
`
`
`
`
`
`
`
`mailed Aug. 17, 2010, filed Sep. 17, 2010 (25 pages).
`
`
`
`
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/820,980, mailed Oct. 28, 2010 (23
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Supplemental Office Action in U.S. Appl. No. 12/820,980, mailed
`
`
`
`
`
`
`
`Nov. 2, 2010 (4 pages).
`
`
`
`Lee & Hayes, Reply after Final (Accelerated Exam-Transmittal
`
`
`
`
`
`
`Reply) in U.S. Appl. No. 12/820,980, mailed Nov. 2, 2010, filed Nov.
`
`
`
`
`
`
`
`
`
`12, 2010 (53 pages).
`
`
`
`
`Advisory Action in U.S. Appl. No. 12/820,980, mailed Nov. 29, 2010
`
`
`
`
`
`
`
`
`
`(3 pages).
`
`
`Lee & Hayes, Reply after Final (Accelerated Exam-Transmittal
`
`
`
`
`
`
`
`Reply) in U.S. Appl. No. 12/820,980, mailed Nov. 2, 2010, filed May
`
`
`
`
`
`
`
`
`
`
`2,2011 (23 pages).
`
`
`
`Office Action in U.S. Appl. No. 12/820,980, mailed Jun. 10,2011 (29
`
`
`
`
`
`
`
`
`
`pages).
`
`Lee & Hayes, Amendment in Reply to Office Action in U.S. Appl.
`
`
`
`
`
`
`
`No. 12/820,980, mailed Jun. 10, 201 1, filedJul. 11, 2011 (115 pages).
`
`
`
`
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/820,980, mailed Sep. 9, 2011 (25
`
`
`
`
`
`
`
`
`
`pages).
`Notice of Abandonment in U.S. Appl. No. 12/820,980, mailed Apr.
`
`
`
`
`
`
`
`11, 2012 (2 pages).
`
`
`
`Office Action in U.S. Appl. No. 12/821,020, mailed Aug. 13, 2010
`
`
`
`
`
`
`
`
`
`(24 pages).
`
`
`Lee & Hayes, Response to Office Action in U.S. Appl. No.
`
`
`
`
`
`
`
`
`12/821,020, mailed Aug. 13, 2010, filed Feb. 14,2011 (18 pages).
`
`
`
`
`
`
`
`
`
`
`Lee & Hayes, Supplemental Reply Amendment in U.S. Appl. No.
`
`
`
`
`
`
`
`12/821,020, filed Apr. 12,2011 (9 pages).
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/821,020, mailed Jun. 27, 2011 (28
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., Amendment in Reply to Office Action, in
`
`
`
`
`
`
`
`U.S. Appl. No. 12/821,020, mailed Jun. 27, 2011, filed Dec. 27,2011
`
`
`
`
`
`
`
`
`
`
`
`(31 pages).
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`002
`
`

`
`
`
`US 8,431,163 B2
`Page 3
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Office Action in U.S.Appl. No. 12/821,020, mailed Jan. 31, 2012 (23
`
`
`
`
`
`
`
`
`
`pages).
`
`Interview Summary in U.S. Appl. No. 12/821,020, mailed Apr. 17,
`
`
`
`
`
`
`
`
`
`2012 (4 pages).
`
`
`Fish & Richardson, P.C., Statement of Substance of Interview and
`
`
`
`
`
`
`
`Comments on Examiner’s Interview Summary, in U.S. Appl. No.
`
`
`
`
`
`
`
`12/821,020, filed Apr. 23, 2012 (8 pages).
`
`
`
`
`
`
`Fish & Richardson, PC., Supplemental Amendment, in U.S. Appl.
`
`
`
`
`
`
`No. 12/821,020, filed Apr. 30, 2012 (10 pages).
`
`
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/821,020, mailed Jun. 15, 2012 (56
`
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., Amendment in Reply, in U.S. Appl. No.
`
`
`
`
`
`
`
`12/821,020, mailed Jun. 15, 2012, filed Aug. 15, 2012 (15 pages).
`
`
`
`
`
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/821,041, mailed Aug. 17, 2010
`
`
`
`
`
`
`
`
`
`
`(32 pages).
`
`
`Lee & Hayes, Reply Amendment in U.S. Appl. No. 12/821,041,
`
`
`
`
`
`
`
`mailed Aug. 17, 2010, filed Feb. 14, 2011 (28 pages).
`
`
`
`
`
`
`
`
`
`
`Lee & Hayes, Supplemental Reply Amendment in U.S. Appl. No.
`
`
`
`
`
`
`
`12/821,041, mailed Aug. 17, 2010, filed Apr. 13,2011 (9 pages).
`
`
`
`
`
`
`
`
`
`Office Action in U.S. Appl. No. 12/821,041, mailed Jun. 27, 2011 (35
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., Amendment in Reply to Office Action in
`
`
`
`
`
`
`
`U.S. Appl. No. 12/821,041, mailed Jun. 27, 2011, filed Jan. 6, 2012
`
`
`
`
`
`
`
`
`
`
`
`(155 pages).
`
`
`Office Action in U.S. Appl. No. 12/821,041, mailed Feb. 10, 2012 (36
`
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., in U.S. Appl. No. 12/821,041, Supplemen-
`
`
`
`
`
`
`
`
`tal Amendment and Remarks, filed May 11, 2012 (32 pages).
`
`
`
`
`
`
`
`
`
`Office Action in U.S.Appl. No. 12/821,041, mailed Jun. 19, 2012 (61
`
`
`
`
`
`
`
`
`
`pages).
`
`Fish & Richardson, P.C., Amendment in Reply to Office Action, in
`
`
`
`
`
`
`
`U.S.Appl.No. 12/821,041,mailedJun. 19,2012,filedAug. 15,2012
`
`
`
`
`(17 pages).
`
`
`Lee & Hayes Amendment in Reply to Office Action in U.S. Appl. No.
`
`
`
`
`
`
`
`
`
`12/820,866, mailed Jun. 8, 2011, filed Jul. 8, 2011 (23 pages).
`
`
`
`
`
`
`
`
`
`Fish & Richardson, Brief on Appeal in U.S. Appl. No. 12/820,866,
`
`
`
`
`
`
`
`
`filed Oct. 4, 2011 (211 pages).
`
`
`
`
`
`Interview Summary in U.S. Appl. No. 12/821,020, mailed Jan. 25,
`
`
`
`
`
`
`
`
`2012 (4 pages).
`
`
`Ameduri et al., Heart Failure in Children, MED-Continuing Medical
`
`
`
`
`
`
`
`Education, University of Minnesota. Jul. 29, 2009 (cited Nov. 12,
`
`
`
`
`
`
`
`
`
`2010); available from URL: ttp://www.cme.unm.edu/prod/groups/
`
`
`
`
`
`med/@pub/@med/@cme/documents/content/med_content_
`
`124593 .pdf.
`
`
`Konduri, “Early inhaled nitric oxide therapy for term and near-term
`
`
`
`
`
`
`
`
`
`
`infants
`with
`hypoxic
`respiratory
`newborn
`failure:
`
`
`
`
`
`
`neurodevelopmental follow-up,” J. Pediatr. vol. 150(3), pp. 235-240,
`
`
`
`
`
`
`
`240.e.1 (2007).
`
`
`Barrington et al., “Inhaled nitric oxide for respiratory failure in
`
`
`
`
`
`
`
`
`
`preterm infants (review),” The Cochrane Collaboration, Wiley Pub-
`
`
`
`
`
`
`
`
`lishers, 3 pages (2009).
`
`
`
`Barst, Pediatr., “Vasodilator Testing with Nitric Oxide and/or Oxy-
`
`
`
`
`
`
`
`
`
`gen in Pediatric Pulmonary Hypertension,” Cardiol., vol. 31, pp.
`
`
`
`
`
`
`
`
`598-606 (2010).
`
`
`Macrae, “Drug therapy in persistent pulmonary hypertension of the
`
`
`
`
`
`
`newborn,” Semin. Neonatal, vol. 2, pp. 49-58 (1997).
`
`
`
`
`
`
`
`Miller et al., “Guidelines for the safe administration of inhaled nitric
`
`
`
`
`
`
`
`
`
`oxide,” Archives of Disease in Childhood, vol. 10, pp. F47-F49
`
`
`
`
`
`
`
`
`
`(1994).
`
`Ovodov et al., “Nitric Oxide: Clinical Applications,” Seminars in
`
`
`
`
`
`
`
`Aneshesia, Saunders, CO, NewYork,, NY, vol. 19, No. 2, pp. 88-97
`
`
`
`
`
`
`
`
`
`
`(2000).
`
`Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects
`
`
`
`
`
`
`
`With Inflammatory Breast Cancer, p. 4, ClinicalTrials.gov, <<http://
`
`
`
`
`
`
`clinicaltrials.gov/ct2/show/NCT00558103>> Apr. 22, 2010.
`
`
`
`
`PCT/US2010/038652 Search Report dated Jul. 29, 2010, 16 pages.
`
`
`
`
`
`
`
`
`Pepke-Zaba et al., “Inhaled nitric oxide as a cause of selective pul-
`
`
`
`
`
`
`
`
`monary vasodilation in pulmonary hypertension,” The Lancet, vol.
`
`
`
`
`
`
`
`338, pp. 1173-1174 (1991).
`
`
`
`
`Ratnasamy et al., “Associations between neurohormonal and inflam-
`
`
`
`
`
`
`
`matory activation and heart failure in children,” American Heart
`
`
`
`
`
`
`
`
`
`Journal, pp. 527-533 (2008).
`
`
`
`
`
`
`
`
`
`Response filed Aug. 18, 2010 to EP Search Report dated May 10,
`
`
`
`
`
`
`
`
`
`
`2010 for EP09251949.
`
`
`
`Ricciardi et al., “Inhaled Nitric Oxide in Primary Pulmonary Hyper-
`
`
`
`
`
`
`
`
`tension: A Safe and Effective Agent for Predicting Response to
`
`
`
`
`
`
`
`
`Nifedipine,” Journal of the American College of Cardiology (JACC)
`
`
`
`
`
`
`
`vol. 32, No. 4, pp. 1068-1073 (1998).
`
`
`
`
`
`
`Roberts, “Inhaled Nitric Oxide and Persistent Pulmonary Hyperten-
`
`
`
`
`
`
`
`
`sion of the Newborn,” The New England Journal of Medicine, vol.
`
`
`
`
`
`
`
`
`
`336, No. 9, pp. 605-610 (1997).
`
`
`
`
`
`Roberts, “Nitric Oxide and the Lung,” Marcel Dekker, Inc., New
`
`
`
`
`
`
`
`
`
`York, NY, pp. 333-363 (1997).
`
`
`
`
`
`Rosales et al., “Hemodynamic Effects Observed with Inhaled Nitric
`
`
`
`
`
`
`
`
`OxideAfter Surgical Repair of Total Anamolous Pulmonary Venous
`
`
`
`
`
`
`
`Return,” Pediatric Cardiology, vol. 20, pp. 224-226 (1999).
`
`
`
`
`
`
`
`
`Rosenberg, “Inhaled nitric oxide in the premature infant with severe
`
`
`
`
`
`
`
`
`
`hypoxemic respiratory failure: A time for caution,” The Journal of
`
`
`
`
`
`
`
`
`Pediatrics, vol. 133, Issue 6 , pp. 720-722 (1998).
`
`
`
`
`
`
`
`Sadiq et al., “Inhaled Nitric Oxide in the Treatment of Moderate
`
`
`
`
`
`
`
`
`Persistent Pulmonary Hypertension of the Newborn: A Randomized
`
`
`
`
`
`Controlled, Multicenter Trial,” Journal of Perinatology, vol. 23, pp.
`
`
`
`
`
`
`
`
`98-103 (2003).
`
`
`Search Report from EP 09251949 dated May 10, 2010.
`
`
`
`
`
`
`
`Sehgal et al., “Experience with Inhaled Nitric Oxide Therapy in
`
`
`
`
`
`
`
`
`Hypoxic Respiratory Failure of the Newborn,” Indian J. Chest Dis.
`
`
`
`
`
`
`
`
`Allied. Sci., vol. 47, pp. 245-249 (2005).
`
`
`
`
`
`
`
`Semigran et al., “Hemodynamic Effects of Inhaled Nitric Oxide in
`
`
`
`
`
`
`
`Heart Failure,” Journal of American College of Cardiology (JACC),
`
`
`
`
`
`
`
`vol. 24, No. 4, pp. 982-988 (1994).
`
`
`
`
`
`
`Shapiro et al., “Diagnostic Dilemmas: Diastolic Heart Failure Caus-
`
`
`
`
`
`
`
`
`ing Pulmonary Hypertension and Pulmonary Hypertension Causing
`
`
`
`
`
`
`
`Diastolic Dysfunction,” Advances in Pulmonary Hypertension, vol.
`
`
`
`
`
`
`5(1), pp. 13-20 (2006) http://www.phaonlineuniv.org/sites/default/
`
`
`
`
`
`files/spr_2006 .pdf.
`
`
`Sibutramine—metf0rmin Combination vs. Sibutramine andMetformin
`
`
`
`
`
`Monotherapy in Obese Patients, p. 3, ClinicalTrials.gov, <<http://
`
`
`
`
`
`
`
`by
`clinicaltrials.gov/ct2/showNCT009413 82>>
`Sponsored
`
`
`
`
`Laboratorios Silanes S.A. de C.V. and Jorge Gonzalez Canudas, Jul.
`
`
`
`
`
`
`
`
`
`15, 2009.
`
`
`Singh et al., “Nitric Oxide, the biological mediator ofthe decade: fact
`
`
`
`
`
`
`
`
`of fiction?,” Eur. Respir. J. , vol. 10, pp. 699-707 (1997).
`
`
`
`
`
`
`
`
`
`Smyth, “Inhaled nitric oxide treatment for preterm infants with
`
`
`
`
`
`
`
`
`
`hypoxic respiratory failure,” Thorax, vol. 55 (Suppl 1), pp. S51-S55
`
`
`
`
`
`
`
`
`(2000).
`
`et
`pediatric
`in
`rehabilitation
`“Exercise
`al.,
`Somarriba
`
`
`
`
`
`
`cardiomyopathy,” Progress in Pediatric Cardiology, vol. 25, pp.
`
`
`
`
`
`
`91-102 (2008).
`
`
`Soto et al., “Cardiopulmonary Hemodynamics in Pulmonary Hyper-
`
`
`
`
`
`
`tension: Pressure Tracings, Waveforms, and More,” Advances in
`
`
`
`
`
`
`
`Pulmonary Hypertension Winter, vol. 7(4), pp. 386-393 (2008).
`
`
`
`
`
`
`
`
`Steinhorn et al., “Inhaled nitric oxide enhances oxygenation but not
`
`
`
`
`
`
`
`
`
`survival in infants with alveolar capillary dysplasia,” The Journal of
`
`
`
`
`
`
`
`
`Pediatrics, pp. 417-422 (1997).
`
`
`
`
`Steinhorn, “Persistent Pulmonary Hypertension in the Newborn and
`
`
`
`
`
`
`
`Infant”, vol. 1(2), pp. 287-299 (1987)
`[downloadedfrom www.
`
`
`
`
`
`
`
`
`Emedicine.com on Jun. 10, 2008.
`
`
`
`
`Persistent-Newborn”,
`Steinhorn,
`“Pulmonary Hypertension,
`
`
`
`
`Updated Apr.
`19, 2007, http://emedicine.medscape.com/article/
`
`
`
`
`
`898437-overview.
`
`Steudel et al., “Inhaled nitric oxide”, Anesthesiology, vol. 91, pp.
`
`
`
`
`
`
`
`
`1090-1121 (1999).
`
`Strauss et al., “Pediatric Cardiomyopathy—A Long Way to Go”, The
`
`
`
`
`
`
`
`
`New England Journal of Medicine, vol. 348, No. 17, pp. 1703-1705
`
`
`
`
`
`
`
`
`
`
`(2003).
`
`Toshniwal, et al., “Study of Comparative Effects of Oral Clonidine
`
`
`
`
`
`
`
`vs. Oral Diazepam Pre-Medication on the Extent and Duration of
`
`
`
`
`
`
`
`
`Sensory Blockade in Patients Undergoing Vaginal Hysterectomy
`
`
`
`
`
`
`Under Spinal Anaesthesia”,
`InterenetJournal of Anesthesiology
`
`
`
`
`
`
`(2009)
`<<http://www.britannica.com/bps/additionalcontent/ 18/
`
`
`41575 5 51/Study-of-Comparative-Effects-Oral-Clonidine-vs-Oral-
`
`
`Diazepam-Pre-Medication-on-the-Extent-and-Duration-of-Sen-
`
`Blockade-in-Patients-Undergoing-Vaginal-Hysterectomy-
`sory-
`
`
`Under-Spinal-Anaesthesia>>.
`
`
`
`
`
`
`
`O03
`
`003
`
`

`
`
`
`US 8,431,163 B2
`Page 4
`
`
`
`
`The American Illustrated Medical Dictionary (Dorland, 7th ed., p.
`
`
`
`
`
`
`
`
`
`1 13) (1914).
`
`
`
`The Effects of Nitric Oxide for Inhalation on the Development of
`
`
`
`
`
`
`
`
`Chronic Lung Disease in Pre-Term Infants, from ClinicalTrials.gov
`
`
`
`
`
`
`
`archive, NCT00551642, Oct. 30, 2007, 3 pages.
`
`
`
`
`
`
`The Encarta Webster’s Dictionary of the English Language (2004) is
`
`
`
`
`
`
`
`the second edition of the Encarta World Dictionary, published 1999,
`
`
`
`
`
`
`
`
`<<http://encarta.msn.com/encnet/features/dictionary/
`
`dictionaryhome.aspx>>; used to look up the definitions of “precau-
`
`
`
`
`
`tion” and “exclusion”.
`
`
`
`The Neonatal Inhaled Nitric Oxide Study Group, The New England
`
`
`
`
`
`
`
`
`
`Journal of Medicine, vol. 336(9), pp. 597-604 (1997).
`
`
`
`
`
`
`
`The NIH, Critical Care Therapy and Respiratory Care Section, Nitric
`
`
`
`
`
`
`
`
`
`
`Oxide Therapy, 13 pages (2000).
`
`
`
`
`Towbin et al., “Incidence, Causes, and Outcomes of Dilated
`
`
`
`
`
`
`
`
`Cardiomyopathy in Children”, JAMA, vol. 296, No. 15, pp. 1867-
`
`
`
`
`
`
`
`
`
`1876 (2006).
`
`
`The Japanese Office Action mailed Feb. 15, 2011 for Japanese Patent
`
`
`
`
`
`
`
`
`
`
`
`Application No. 2009-157623, a counterpart foreign application for
`
`
`
`
`
`
`
`U.S. Appl. No. 12/494,598.
`
`
`
`
`Troncy et al. “Inhaled nitric oxide: clinical applications, indications,
`
`
`
`
`
`
`
`
`and toxicology”, Can. J. Anaesth, vol. 44 (9), pp. 972-988 (1997).
`
`
`
`
`
`
`
`
`
`UCI General Clinical Research Center, Federal Regulations 21 CFR
`
`
`
`
`
`
`
`
`Part 312, <<http://www.gcrc.uci.edu/rsa/aer.cfm>>, retrieved Sep.
`
`
`
`
`
`13, 2010, 2 pages.
`
`
`
`University of Alabama, NCT00732537 at Clinicaltrials. gov (2008).
`
`
`
`
`
`
`“Use of Inhaled Nitric Oxide”, American Academy of Pediatrics—
`
`
`
`
`
`
`
`Committee on Fetus and Newborn, Pediatrics vol. 106, No. 2, pp.
`
`
`
`
`
`
`
`
`
`344-345 (2000).
`
`
`UTMB Respiratory Care Services, “Delivery of Inhaled Nitric Oxide
`
`
`
`
`
`
`
`
`Therapy through an Adult or Pediatric Nasal Carmula,” 4 pages
`
`
`
`
`
`
`
`
`(2003).
`
`van Dalen, “Treatment for Asymptomatic Anthracycline-Induced
`
`
`
`
`
`
`Cardiac Dysfunction in Childhood Cancer Survivors: The Need for
`
`
`
`
`
`
`
`Evidence,” Journal of Clinical Oncology, vol. 21, No. 17, pp. 3375-
`
`
`
`
`
`
`
`
`
`
`3379 (2003).
`
`
`Watson et al., “Clinical and Economic Effects of iNO in Premature
`
`
`
`
`
`
`
`
`Newborns With Respiratory Failure at 1 Year”, Pediatrics, vol. 124,
`
`
`
`
`
`
`
`
`pp. 1333-1343 (2009).
`
`
`
`Weinberger et al., “The Toxicology of Inhaled Nitric Oxide,” Toxi-
`
`
`
`
`
`
`
`
`cological Sciences, vol. 59, pp. 5-16 (2001).
`
`
`
`
`
`
`
`Weinberger et al., “Nitric Oxide in the lung: therapeutic and cellular
`
`
`
`
`
`
`
`
`
`mechanisms of action,” Pharmacology & Therapeutics, vol. 84, pp.
`
`
`
`
`
`
`
`401-411 (1999).
`
`Wessel et al., “Improved Oxygenation in a Randomized Trial of
`
`
`
`
`
`
`
`Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the
`
`
`
`
`
`
`
`
`Newborn,” Pediatrics, vol. 100, No. 5, p. E7 (1997).
`
`
`
`
`
`
`
`Wessel et al., “Managing low cardiac output syndrome after congeni-
`
`
`
`
`
`
`
`
`
`tal heart surgery,” Crit. Care Med., vol. 29(10) pp. S220-S230 (2001).
`
`
`
`
`
`
`
`
`
`
`
`Wheeler et al., “The Central Nervous System in Pediatric Critical
`
`
`
`
`
`
`
`
`Illness and Injury,” Pediatric Critical Care Medicine, Springer, p. 278
`
`
`
`
`
`
`
`
`
`(2007).
`
`Wilkinson et al., “Epidemiological and outcomes research in children
`
`
`
`
`
`
`
`with pediatric cardiomyopathy; discussions from the international
`
`
`
`
`
`
`
`workshop on primary and idiopathic cardiomyopathies in children,”
`
`
`
`
`
`
`Progress in Pediatric Cardiology, vol. 25, pp. 23-25 (2008).
`
`
`
`
`
`
`
`
`Yoshida, “Well-illustrated Diagnostics and Treatment of Heart Fail-
`
`
`
`
`
`
`
`ure,” Professor of Kawasaki Medical University, cardiovascular
`
`
`
`
`
`
`
`internal medicine, Circulation, Up-to-Date vol. 2, No. 4, pp. 23-28
`
`
`
`
`
`
`
`
`(2007).
`
`Fish & Richardson P.C., Supplemental Remarks in U.S. Appl. No.
`
`
`
`
`
`
`
`12/821,020, filed May 9, 2012 (22 pages).
`
`
`
`
`
`
`Fish & Richardson P.C., Statement of the Substance of the Interview
`
`
`
`
`
`
`and Comments on Examiner’ s Interview Summary, in U.S. Appl. No.
`
`
`
`
`
`
`
`
`12/821,020, mailed Jan. 25, 2012, filed Feb. 27, 2012 (7 pages).
`
`
`
`
`
`
`
`
`
`
`Examiner’s Answer in U.S. Appl. No. 12/820,866, mailed Nov. 2,
`
`
`
`
`
`
`
`
`2011 (27 pages).
`
`
`
`Notice ofAbandonment in U.S. Appl. No. 12/820,866, mailed Dec.
`
`
`
`
`
`
`
`20, 2012 (2 pages).
`
`
`
`Adatia eta1., “Inhaled Nitric Oxide and Hemodynamic Evaluation of
`
`
`
`
`
`
`
`
`Patients With Pulmonary Hyptertension Before Transplantation,”
`
`
`
`
`
`
`Journal of the American College of Cardiology, Elsevier, NewYork,
`
`
`
`
`
`
`
`NY, vol. 25, No. 7, p. 1663, Jun. 1, 1995.
`
`
`
`
`
`
`
`
`
`
`
`
`004
`
`Advances in Pulmonary Hypertension, vol. 7(4), pp. 1-418, Winter
`
`
`
`
`
`
`
`2008-2009 (entire issue).
`
`
`
`Al-Alaiyan et al., “Inhaled nitric oxide in persistent pulmonary
`
`
`
`
`
`
`
`hypertension of the newborn refractory to high-frequency ventila-
`
`
`
`
`
`
`tion,” Crit. Care, vol. 3, No. 1, pp. 7-10 (1999).
`
`
`
`
`
`
`
`
`Argenziano et al., “Inhaled Nitric Oxide is not a Myocardial Depres-
`
`
`
`
`
`
`
`
`sant in a Porcine Model of Heart Failure,” The Journal of Thoracic
`
`
`
`
`
`
`
`
`and Cardiovascular Surgery, vol. 115, pp. 700-704 (1998).
`
`
`
`
`
`
`
`
`Atz et al., “Combined Effects of Nitric Oxide and Oxygen During
`
`
`
`
`
`
`
`
`
`Acute Pulmonary Vasodilator Testing,” Journal ofthe American Col-
`
`
`
`
`
`
`
`lege of Cardiology (JACC), vol. 33, No. 3, pp. 813-819 (1999).
`
`
`
`
`
`
`
`
`
`Atz et al., “Inhaled nitric oxide in the neonate with cardiac disease,”
`
`
`
`
`
`
`
`
`
`Seminars in Perinatology, vol. 21(5), pp. 441-455 (1997).
`
`
`
`
`
`
`
`AU 2009202685 Office Action dated Jun. 17, 2010 (3 pages).
`
`
`
`
`
`
`
`
`
`AU 2009202685 Office Action Response dated Jul. 29, 2010, 19
`
`
`
`
`
`
`
`
`
`pages.
`Azeka et al., “Effects of Low Doses of Inhaled Nitric Oxide Com-
`
`
`
`
`
`
`
`
`
`bined with Oxygen for the Evaluation of Pulmonary Vascular Reac-
`
`
`
`
`
`
`
`
`tivity in Patients with Pulmonary Hypertension,” Pedatric Cardio1.,
`
`
`
`
`
`
`
`vol. 23, pp. 20-26 (2002).
`
`
`
`
`
`Barrington et al., “Inhaled Nitric Oxide for Preterm Infants: A Sys-
`
`
`
`
`
`
`
`tematic Review,” Pediatrics, vol. 120; pp. 1088-1099, DOI: 10.1542/
`
`
`
`
`
`
`
`
`
`peds (2007).
`
`
`Barst et al., “Nitric Oxide in Combination with Oxygen versus Either
`
`
`
`
`
`
`
`
`
`Oxygen Alone or Nitric Oxide Alone for Acute Vasodilator Testing in
`
`
`
`
`
`
`
`
`Children with Pulmonary Hypertension